Remove 2028 Remove Dosage Remove Immunity
article thumbnail

PROTAC development gains momentum, but clinical performance is poor

Pharmaceutical Technology

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. GlobalData’s analyst consensus forecast database estimates peak annual sales for ARV-110 of $325 million in 2028.

Dosage 59
article thumbnail

N-FIS was developed to address a critical challenge in healthcare—needle phobia

Express Pharma

Key parameters, such as pressure and orifice size, are carefully calibrated to achieve accurate drug delivery at the desired depth and dosage, making it a safe and efficient alternative to traditional needle injections. billion in 2028, growing at a compound annual growth rate (CAGR) of 14.16 What are the projections?